Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sarah Cannon

Dermatology Bel Air, MD Medical Doctor

NPI 1821319229 CMS profile 174120

2012 S Tollgate Rd Ste 206, Bel Air, MD 21015

Open in the dashboard

General payments

$8,359

424 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Cannon of Bel Air, MD is reported in the CMS Open Payments database as having received $8,359 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,346 61
2024 General $2,006 116
2023 General $2,054 103
2022 General $1,207 62
2021 General $928 43
2020 General $427 24
2019 General $390 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Cannon
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Sarah Cannon were reported at $1,346. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Sarah Cannon Dermatology median Middle half National median
2019 $390 $454 $129–$1,240 $163
2020 $427 $235 $81–$756 $114
2021 $928 $377 $108–$1,108 $132
2022 $1,207 $514 $143–$1,391 $149
2023 $2,054 $607 $159–$1,674 $160
2024 $2,006 $751 $204–$1,903 $164
2025 $1,346 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,850 119 payments
  2. AbbVie, Inc. $1,420 69 payments
  3. Sun Pharmaceutical Industries Inc. $791 34 payments
  4. Genzyme Corporation $564 24 payments
  5. Lilly USA, LLC $545 28 payments
  6. Galderma Laboratories, L.P. $535 19 payments
  7. Pfizer Inc. $507 23 payments
  8. Amgen Inc. $384 20 payments
  9. Regeneron Healthcare Solutions, Inc. $353 14 payments
  10. Incyte Corporation $252 13 payments
  11. Other $1,160 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,089 420 payments
  2. Education $270 4 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $1,234 78 payments
  2. SIMPONI ARIA $958 68 payments
  3. STELARA $958 68 payments
  4. SIMPONI $958 68 payments
  5. DUPIXENT $799 34 payments
  6. SKYRIZI $743 37 payments
  7. REMICADE $615 41 payments
  8. Winlevi $615 27 payments
  9. RINVOQ $492 21 payments
  10. Absorica LD $484 21 payments
  11. Other $4,677 232 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

34

Median for Dermatology: 534

Drug cost

$821

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 17 $641
Ketoconazole Generic 17 $180

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $349
$349 — —
Otezla
  • Amgen Inc. $169
$169 — —
SKYRIZI
  • AbbVie, Inc. $156
$156 — —
Winlevi
  • Sun Pharmaceutical Industries Inc. $144
$144 — —
DUPIXENT
  • GENZYME CORPORATION $96
  • Regeneron Healthcare Solutions, Inc. $20
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record